These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7531941)

  • 1. Sterility of unit dose syringes of filgrastim and sargramostim.
    Singh RF; Corelli RL; Guglielmo BJ
    Am J Hosp Pharm; 1994 Nov; 51(22):2811-2. PubMed ID: 7531941
    [No Abstract]   [Full Text] [Related]  

  • 2. Sterility of repackaged filgrastim and sargramostim.
    Kleinberg ML
    Am J Health Syst Pharm; 1995 May; 52(10):1101. PubMed ID: 7544685
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment: filgrastim sterility in syringes.
    Trissel LA; Spadoni VT
    Ann Pharmacother; 1997 Apr; 31(4):500-1. PubMed ID: 9101020
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions.
    Kellihan MJ
    Clin Ther; 1993; 15(5):927-37. PubMed ID: 7505717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of biologic response modifiers.
    Louie SG; Jung B
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S10-8. PubMed ID: 7689788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction.
    Engler RJ; Weiss RB
    Ann Allergy Asthma Immunol; 1996 Jun; 76(6):531-4. PubMed ID: 8673688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sterility of filgrastim (G-CSF) in syringes.
    Jacobson PA; West NJ; Spadoni V; Maksym CJ; Pierson C
    Ann Pharmacother; 1996 Nov; 30(11):1238-42. PubMed ID: 8913403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Big cost savings from small filgrastim unit doses.
    Sinsabaugh DK; Freyer DR
    Am J Hosp Pharm; 1993 Jul; 50(7):1363-4. PubMed ID: 7689787
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Colony stimulating factors in blood formation].
    Goebel M
    Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():51-6. PubMed ID: 7531048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on prolactin and adrenocorticotropic hormone secretion in rats: dose- and time-response in vivo studies.
    Komorowski J; Zylińska K; Mucha S; Robak T; Wrzesien-Kus A; Stepień H
    Cytobios; 1996; 86(346):147-53. PubMed ID: 9022262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
    Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filgrastim post-chemotherapy mobilizes more CD34+ cells compared to its use during steady-state haemopoiesis.
    Perez-Oteyza J; Garcia-Laraña J; Ramos P; Zamora C; Lopez-Jimenez J; Roldan E; Odriozola J
    Bone Marrow Transplant; 1995 Aug; 16(2):324-5. PubMed ID: 7581160
    [No Abstract]   [Full Text] [Related]  

  • 14. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Getting the most out of low-dose syringe prefilling of a high-cost biotechnology agent.
    Lu A; Chan L
    Hosp Pharm; 1994 Apr; 29(4):353, 356-7. PubMed ID: 10133464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
    Nissen C
    Eur J Cancer; 1994; 30A Suppl 3():S12-4. PubMed ID: 7535065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
    Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ
    J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality control guidelines for single unit packaging of parenterals in the hospital pharmacy.
    Patel JA; Curtis EG; Phillips GL
    Am J Hosp Pharm; 1972 Nov; 29(11):947-51. PubMed ID: 4655003
    [No Abstract]   [Full Text] [Related]  

  • 19. Granulocyte colony-stimulating factor administration and monocyte phenotype.
    Ohsaka A
    Exp Hematol; 1996 Jun; 24(7):767. PubMed ID: 8647225
    [No Abstract]   [Full Text] [Related]  

  • 20. Peripheral blood mononuclear mobilization with sargramostim (GM-CSF).
    Ahmed T; Preti RA; Razis E; Farley T; Lake DE; Beer M; Cook P; Ciavarella D
    Prog Clin Biol Res; 1994; 389():457-62. PubMed ID: 7535454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.